| Cerebrospinal fluid lipoproteins inhibit α-synuclein aggregation by interacting with oligomeric species in seed amplification assays G Bellomo, S Paciotti, L Concha-Marambio, D Rizzo, AL Wojdaƚa, ... Molecular Neurodegeneration 18 (1), 20, 2023 | 15 | 2023 |
| Methods to discover and validate biofluid-based biomarkers in neurodegenerative dementias CE Teunissen, L Kimble, S Bayoumy, K Bolsewig, F Burtscher, ... Molecular & Cellular Proteomics 22 (10), 2023 | 13 | 2023 |
| Multi-omics interdisciplinary research integration to accelerate dementia biomarker development (MIRIADE) E Mavrina, L Kimble, K Waury, D Gogishvili, S Das, S Coppens, ... Frontiers in Neurology 13, 890638, 2022 | 12 | 2022 |
| Fully automated measurement of plasma Aβ42/40 and p‐tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in … G Bellomo, S Bayoumy, A Megaro, A Toja, G Nardi, L Gaetani, ER Blujdea, ... Alzheimer's & Dementia, 2024 | 5 | 2024 |
| Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer’s disease continuum S Paciotti, AL Wojdała, G Bellomo, A Toja, E Chipi, SR Piersma, TV Pham, ... Alzheimer's Research & Therapy 15 (1), 124, 2023 | 4 | 2023 |
| Estres y drogadiccion: una perspectiva actualizada para 2020/Stress and drug addiction: an up-to-date perspective from 2020. A Wojdala, F Molins, MA Serrano Adicciones 32 (4), 239-242, 2020 | 4 | 2020 |
| CSF and plasma Aβ42/40 across Alzheimer’s disease continuum: comparison of two ultrasensitive Simoa® assays targeting distinct amyloid regions AL Wojdała, G Bellomo, A Toja, L Gaetani, L Parnetti, D Chiasserini Clinical Chemistry and Laboratory Medicine (CCLM) 62 (2), 332-340, 2024 | 3 | 2024 |
| Investigating alpha‐synuclein co‐pathology in Alzheimer's disease by means of cerebrospinal fluid alpha‐synuclein seed amplification assay G Bellomo, A Toja, F Paolini Paoletti, Y Ma, CM Farris, L Gaetani, ... Alzheimer's & Dementia, 2024 | 2 | 2024 |
| Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: disease staging by NF-L, p-tau181, and GFAP AL Wojdała, G Bellomo, L Gaetani, A Toja, E Chipi, D Shan, D Chiasserini, ... Neurobiology of Disease 189, 106356, 2023 | 2 | 2023 |
| Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer’s Disease: ELISA Development and Clinical Validation AL Wojdała, D Chiasserini, G Bellomo, S Paciotti, L Gaetani, FP Paoletti, ... Journal of Alzheimer's Disease 88 (4), 1459-1468, 2022 | 2 | 2022 |
| Targeting multiphosphorylated tau: technical and clinical validation of a new Simoa® assay for CSF and plasma detection of tau simultaneously phosphorylated at T181 and T231 AL Wojdała, G Bellomo, L Gaetani, D Shan, L Parnetti, D Chiasserini medRxiv, 2023.06. 08.23291128, 2023 | | 2023 |
